Acadia Pharmaceuticals, based in San Diego, CA, is a pioneering company at the forefront of neuroscience breakthroughs, dedicated to elevating life. With over 25 years of experience, Acadia is committed to providing vital solutions to address unmet medical needs. Their FDA-approved treatments, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome, have revolutionized the field, while their ongoing clinical-stage developments focus on addressing negative symptoms in schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Driven by a mission to fight diseases and ensure a brighter future for all, Acadia is united in their commitment to elevating life. They embrace diverse perspectives, foster collaboration, and stand resilient in their dedication to developing innovative therapies in areas with high unmet needs. With a focus on patient support, education, and connection, Acadia goes beyond therapies to help patients in their fight against diseases.
Generated from the website